Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells $58,470.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) CFO Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the transaction, the chief financial officer now directly owns 177,195 shares in the company, valued at approximately $5,315,850. The trade was a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Colleen Tupper also recently made the following trade(s):

• On Tuesday, March 11th, Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.01, for a total value of $313,454.45.

Collegium Pharmaceutical Trading Up 1.6 %

NASDAQ COLL traded up $0.46 during trading hours on Friday, hitting $29.56. 147,740 shares of the company were exchanged, compared to its average volume of 391,784. The stock has a market cap of $930.57 million, a PE ratio of 12.74 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 52 week low of $27.27 and a 52 week high of $42.29. The stock has a 50-day moving average price of $30.85 and a 200 day moving average price of $33.05. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

COLL has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Piper Sandler decreased their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $43.60.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after buying an additional 175,892 shares in the last quarter. Penserra Capital Management LLC bought a new stake in Collegium Pharmaceutical during the 3rd quarter valued at $757,000. Barclays PLC raised its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after purchasing an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 10.7% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company's stock worth $695,000 after buying an additional 1,731 shares during the period. Finally, FMR LLC grew its position in shares of Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company's stock worth $1,459,000 after buying an additional 35,439 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.